An anxiolytic drug buspirone ameliorates hyperglycemia and endothelial dysfunction in type 2 diabetic rat model; [Anksiyolitik bir ilaç olan buspiron tip 2 diyabet sıçan modelinde hiperglisemi ve endotelyal disfonksiyonu düzeltiyor]

Simple item page
dc.contributor.authorÇavuşoğlu T.G.
dc.contributor.authorDarıverenli E.
dc.contributor.authorVural K.
dc.contributor.authorEkerbicer N.
dc.contributor.authorUlman C.
dc.contributor.authorÖlmez E.
dc.contributor.authorUysal N.
dc.date.accessioned2024-07-22T08:07:19Z
dc.date.available2024-07-22T08:07:19Z
dc.date.issued2020
dc.description.abstractObjectives: Type 2 diabetes is a common metabolic disease and anxiety disorders are very common among diabetics. Buspirone is used in the treatment of anxiety, also having blood glucose-lowering effects. The aim of the study was to investigate the effects of buspirone on the glucose and lipid metabolism as well as vascular function in type 2 diabetic rats. Methods: A type 2-diabetic model was induced through a high-fat diet for eight weeks followed by the administration of low-dose streptozotocin (35 mg/kg, intraperitoneal) in rats. Buspirone was given at two different doses (1.5 mg/kg/d and 5 mg/kg/d) and combined with metformin (300 mg/kg/d). The fasting glucose and insulin levels, lipid profile were analyzed, and vascular response measured from the thoracic aorta was also evaluated. Results: Both doses of buspirone caused a significant improvement in fasting blood glucose levels. In particular, the buspirone treatment, combined with metformin, improved endothelial dysfunction and was found to be correlated with decreased nitrate/nitrite levels. Conclusions: Buspirone may be effective in the treatment of type 2 diabetes, either alone or in combination with other treatments, particularly in terms of endothelial dysfunction, inflammation and impaired blood glucose, and insulin levels. © 2020 De Gruyter. All rights reserved.
dc.identifier.DOI-ID10.1515/TJB-2019-0224
dc.identifier.issn02504685
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13920
dc.language.isoEnglish
dc.publisherDe Gruyter Open Ltd
dc.rightsAll Open Access; Gold Open Access
dc.subjectacetylcholine
dc.subjectanxiolytic agent
dc.subjectbuspirone
dc.subjectC reactive protein
dc.subjectcarbohydrate
dc.subjectcholesterol
dc.subjectfat
dc.subjectglucose
dc.subjecthigh density lipoprotein
dc.subjecthigh density lipoprotein cholesterol
dc.subjectmalonaldehyde
dc.subjectmetformin
dc.subjectnitrate
dc.subjectnitric oxide
dc.subjectnitroprusside sodium
dc.subjectolanzapine
dc.subjectphenylephrine
dc.subjectprotein
dc.subjectstreptozocin
dc.subjectsuperoxide dismutase
dc.subjecttriacylglycerol
dc.subjecturethan
dc.subjectvery low density lipoprotein
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectantidepressant activity
dc.subjectArticle
dc.subjectbiochemical analysis
dc.subjectblood analysis
dc.subjectblood vessel reactivity
dc.subjectbody weight
dc.subjectcardiovascular risk
dc.subjectcircadian rhythm
dc.subjectcontrolled study
dc.subjectdiastolic blood pressure
dc.subjectendothelial dysfunction
dc.subjectenzyme linked immunosorbent assay
dc.subjectglucose blood level
dc.subjectglycemic control
dc.subjectheart rate
dc.subjecthomeostasis model assessment
dc.subjecthyperglycemia
dc.subjectinflammation
dc.subjectinsulin level
dc.subjectinsulin resistance
dc.subjectlipid analysis
dc.subjectlipid diet
dc.subjectlipid fingerprinting
dc.subjectlipid metabolism
dc.subjectmale
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectprevalence
dc.subjectrat
dc.subjectsensitivity analysis
dc.subjectsystolic blood pressure
dc.subjectthoracic aorta
dc.subjectvascular activity
dc.titleAn anxiolytic drug buspirone ameliorates hyperglycemia and endothelial dysfunction in type 2 diabetic rat model; [Anksiyolitik bir ilaç olan buspiron tip 2 diyabet sıçan modelinde hiperglisemi ve endotelyal disfonksiyonu düzeltiyor]
dc.typeArticle

Files

Collections

Scopus Koleksiyonu